StemCell Therapy

Italian health officials are allowing a handful of patients to continue with a controversial stem cell therapy amid protests from scientists that the treatments are unproven and unsafe.

The Stamina Foundation has been administering the therapy at the public hospital Spedali Civili of Brescia to people with a range of degenerative diseases. Their approach is based on mesenchymal stem cells, derived from bone marrow, which can become mature bone and connective tissue.

In 2011 the hospital agreed to host the research and assist with cell extraction and patient treatments, stirring protests from the medical community. "The hospital is not even listed among the 13 Italian authorised stem cell factories," says Michele de Luca, director and gene therapy programme coordinator at the Centre for Regenerative Medicine in Modena. After an inspection in 2012, Italian drug regulator AIFA ordered an immediate halt to Stamina's stem cell treatments at the hospital.

The AIFA report says the Stamina Foundation's treatment did not follow Italy's official path required for clinical approval. So far no scientific publications describing its effectiveness are available.

But the halt sparked protests among patients' families who believed the treatment was working. Some appealed to the courts, and as a result a few patients were allowed to go ahead with the therapy. On 15 March, a group of 13 Italian stem cell researchers published an open letter to the country's Minister of Health, Renato Balduzzi, asking him to shut down all of the Stamina Foundation's treatments at the hospital.

Instead Balduzzi signed a bill last week authorising the foundation to continue treatments in patients who had already begun the regime unless they are experiencing serious side effects.

If you would like to reuse any content from New Scientist, either in print or online, please contact the syndication department first for permission. New Scientist does not own rights to photos, but there are a variety of licensing options available for use of articles and graphics we own the copyright to.

Only subscribers may leave comments on this article. Please log in.

Only personal subscribers may leave comments on this article

Subscribe now to comment.

Go here to read the rest:
Italy pushes on with controversial stem cell therapy

Albany, NY (PRWEB) March 29, 2013

GBI Research, the leading business intelligence provider, has released its latest research Stem Cell Therapy Market in Asia-Pacific to 2018 Commercialization Supported by Favorable Government Policies, Strong Pipeline and Increased Licensing Activity. The report provides an in-depth analysis on stem cell research and development in India, China, Japan, South-Korea and Singapore. The report market analysis and forecasts for CABG, LSCT, Type 1 DM, Type 2 DM, Hearticellgram, Cerecellgram, Cartistem and Cupistem. The report also provides information on trends and pipelines. In addition to this, the report covers market drivers and challenges for stem cell research market.

To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis/155690

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Researchs team of industry experts.

GBI Research analysis finds the stem cell therapy market was valued at $545m in 2012, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10% from 2012 to 2018, to attain a value of $972m in 2018. The market is poised for significant growth in the forecast period due to the anticipated launch of JCR Pharmaceuticals JR-031 (2014) in Japan and FCB Pharmicells Cerecellgram (CCG) (2015) in South Korea.

Related Report: Mobile Health (mHealth) - Enhancing Healthcare and Improving Clinical Outcomes

The research is mainly in early stages, with the majority of the molecules being in early stages of development (Phase I/II and Phase II). Phase I/II and Phase II contribute 67% of the pipeline. Stem cell research is dominated by hospitals/universities/institutions, which contribute 63% of the molecules in the pipeline. The dominance of institutional research is attributable to uncertain therapeutic outcomes in stem cell research.The major companies conducting research in India include Reliance Life Sciences and Stempeutics Research Pvt Ltd, among others. The major institutions include PGIMER and AIIMS.

Latest Report: Global SMB Web Analytics Market 2012-2016

Scope

Healthcare Report: Generic Growth Strategies - Market Driven by Impending Patent Cliff, Declining R&D Productivity and Government Initiatives to Reduce Healthcare Costs

Read more:
Stem Cell Therapy Market in Asia-Pacific to 2018 Market Research Report Available at MarketResearchReports.biz

Stem Cell Therapy for Pets -- Midnight Before After
Amazing before and after footage of Midnight, a dog who received stem cell therapy for her arthritic joints. We discovered a side benefit of better skin and ...

By: NewmanVets

Read the original here:
Stem Cell Therapy for Pets -- Midnight Before

By: Azer N. Parrocha, Philippine News Agency March 28, 2013 3:16 AM

InterAksyon.com The online news portal of TV5

MANILA, Philippines - Although guidelines for stem cell therapy in the country have already been released, the Department of Health (DOH) on Wednesday reminded the public that hospitals performing the treatment are as of the moment, not accredited.

Health Secretary Enrique Ona, in a press conference, explained that for a hospital or clinic to be considered accredited, a years worth of tests and studies have to be done to prove that the procedure is indeed safe and effective.

I hope the general public understands that these stem cells, although called innovative (form of treatment) is not standard and should not be advertised as though it is already an accepted form of treatment, Ona said.

Ona explained that the DOH still continues to look on the capacity of the treatment and will make sure that the stem cells used for procedure are accepted as protocol.

Stem cells like those coming from embryos or animals which are restricted will also be looked into by the DOH to see if there are any hospitals or clinics that do not abide by the administrative order.

If the protocol is accepted, report of results should be evaluated, he said. They are evaluated about a year to see if their claim is effective [and if it is] it will be validated.

At present, there are no hospitals or clinics completely accredited for the stem cell therapy yet. Given that, certain processes must be followed before doctors are allowed to use the treatment.

I cannot see a so-called clinic yet certifying that there is a process that is very effective, Ona explained. We have to see the type of stem cell, the type of claim they have.

Link:
Hospitals performing stem cell therapy are yet to be accredited – DOH

Stem Cell Therapy for Pets - Guiness Before After
Amazing before and after footage of Guiness, an 11 year old dog who received stem cell therapy for his arthritis and got an unexpected side benefit. For more...

By: NewmanVets

See the rest here:
Stem Cell Therapy for Pets - Guiness Before

Stem Cell Therapy for Pets - Sammy Before After
Amazing before and after footage of Sammy, a yellow lab who received stem cell therapy for his arthritic joints. For more information about stem cell therapy...

By: NewmanVets

Read the original:
Stem Cell Therapy for Pets - Sammy Before

The Consumer By Linda Bolido Philippine Daily Inquirer

All the publicity about stem-cell therapy (SCT), including endorsements from some of the countrys most powerful people and brightest stars, has made it seem like a miracle cure, even a cure-all.

From the treatment of life-threatening medical problems to reversing the effects of aging, people are now beginning to look to SCTespecially if they can afford itfor salvation.

But, according to a doctor I know, there are actually only two proven applications for the therapy right now. The rest, at this stage, is really still experimental. People have, of course, volunteered for pioneering procedures, hoping for a cure for whatever ails them.

Education still needed

Thats well and good, as long as they are fully informed and give their unequivocal consent to being experimented on. The problem, however, is some people undergo the therapy without fully understanding it. And there are groups that seem to think that because they have Googled the therapy and read everything on the Net about it, they are capable of doing the procedure.

I mentioned in this column previously that even beauty parlors were offering to do SCT. Although it would be only for cosmetic purposes, the procedure is too new and complex to leave in the hands of beauticians.

Finally, the Department of Health has issued rules and regulations to regulate the SCT practice, a move warmly welcomed by the medical community, particularly the Philippine Medical Association and Philippine Society for Stem Cell Medicine, which expressed concern before that the popularity of SCT would lead to abuse and illegal practice if left unregulated.

Health Secretary Enrique Ona, in published reports, said the guidelines aimed to safeguard the welfare of our patients and the general public by making [sure] safe, effective and ethical stem-cell modalities and practices are within emerging international and global standards considering the very complex nature of this therapy.

Among other things, the rules restrict the use of genetically altered stem cells and tissues of human adults and the umbilical cord, fat-derived human stem cells and live animal stem cells.

View original post here:
New rules will regulate stem- cell therapy use

Retina Consultants of Southwest Florida

Dr. Ashish Sharma of Retina Consultants of Southwest Florida conducts an eye exam.

The Naples seminar will be from 1 p.m. to 4 p.m. at the Hilton Naples, 5111 U.S. 41 North.

An identical seminar in Fort Myers will be Monday from 9 a.m. to noon at Harborside Convention Center, 1375 Monroe St.

To register to attend, call 1-866-946-6824, or go to http://www.MassEyeAndEar.organization/symposium.

NAPLES Leonard Klein plays tennis and bridge, and both of his games could improve if he has stem cell therapy some day.

The 80-year-old suffers from dry macular degeneration. While his vision loss hasnt worsened in recent months, theres no telling the future.

Studies are under way to see if stem cell therapy can reverse vision loss for people suffering from age-related macular degeneration.

Klein will sign up if such a study opens up to Southwest Florida.

Im a risk taker and always have been, he said recently, before heading to a bridge game in the care center at the Vi at Bentley Village, a continuing care retirement community in North Naples.

Continued here:
Naples seminar to look at stem cell therapy to aid macular degeneration

By Amads Ma. Guerrero Philippine Daily Inquirer

INFORMATION booth

You feel like you have entered an attractive boutique hotel in miniature; everything is neat, clean, almost spotless and sparkling.

This is the Asian Aesthetic Center in Katipunan Avenue, Quezon City (contact number: 7099565) across the Ateneo de Manila. The equipment is state-of-the-art, and there are two main wings: The Dermatology Wing and the Surgical Wing.

In the Dermatology Wing we have a Laser Room, Slimming Room, a Wellness Room and a Facial Treatment Room. The Surgical Room was what interested me mostbut only as a writer and not personally, because my cells are not dysfunctional (to my knowledge!).

Unfortunately, colleague Neilsen and I could not enter the Surgical Wing because a procedure was under way. In this wing, we were told, is a stem cell laboratory unit with the stem cell extractor and activator machines, and a recovery room, along with other amenities.

The clinic is cozy and family-run, you might say. It is headed by Dr. Amy B. Tinaza, a cosmetic surgeon and a stem cell specialist, and her partner (professional as well as personal) Dr. Jomar S. Tinaza, chief facial plastic surgeon and her husband. And the centers PR is a sister in law, Charlotte Tinaza.

The Tinaza couple head the Stem Cell Therapy Team, and there are also Medical, Surgical, Specialist and After-Care Teams.

So why did she (Dr. Amy) choose to be a stem cell specialist? Although stem cell therapy is at an early stage, I believe it is the future of medicine, she replies.

The centers stem cell therapy is the Autologous Fat Stem Cell, in which the stem cell is from the fat cells of the same patient, and transferred back to the patient once the stem cell is activated.

See the rest here:
Stem cell therapy –how profitable?

The Department of Health (DOH) has restricted hospitals and other facilities from using genetically-altered cells and tissues of human in carrying out stem-cell therapy and treatments in the country. Health secretary Enrique Ona added that their department also prohibits the use of umbilical cord, fat-derived human stem cells, and live animal stem cells for the conduct of the procedure locally.

Related story: Foundation seeks to help people on the verge of suicide On Wednesday, DOH released Administrative Order (AO) 2013-0012 which seeks to ensure the safety of people who want to undergo human stem cell and cell-based therapies.

The AO also prohibits for human treatment and research the creation of human embryos and their derivatives, the use of aborted human fetal stem cells and their derivatives, and plant parts labeled as stem cells, the order stated. Ona hopes AO will make effective and ethical stem cell modalities and practices that will be at par with emerging international and global standards on the very complex nature of this therapy.

Also read: Genetically modified crops threaten organic agriculture He explained the AO also hopes to prevent the introduction, transmission, and spread of communicable diseases by ensuring a minimum quality of service and staff qualification rendered by hospitals and other health facilities capable of utilizing human stem cell preparations and cell-based therapies. These guidelines will classify which stem cell preparations and therapies will be registered and allowed with certain restrictions, Ona said in a statement. Preparations that will be allowed include those with adult human stem cells, human umbilical cord stem cells, and human organ-specific cells, he noted.

Related story: Fresh food make up most of Pinoys' shopping basket, says study He explained that health facilities utilizing stem cell preparations and cell-based or cellular therapies will be mandated to comply with the guidelines set by DOHs Bioethics Advisory Board. The Borad, Ona notes, will ensure that ethical and professional standards are upheld and that contentious scientific, ethical and legal issues are addressed. He said charges and complaints shall be addressed to the DOH Bureau of Health Facilities & Services and the Philippine Food and Drug Agency. Stem cell therapy and treatments are medical procedures where doctors replace malignant cells with healthier cells in an effort to cure or address ailments like cancer. Some facilities also use the procedure for cosmetic purposes, targeting components of the skin like collagen to make patients look younger and healthy.

See the original post here:
DOH restricts hospitals amid stem- cell therapy craze

Editor's Choice Academic Journal Main Category: Lymphoma / Leukemia / Myeloma Also Included In: Stem Cell Research Article Date: 21 Mar 2013 - 12:00 PDT

Current ratings for: Cell Therapy Shows Promise For Advanced Leukemia In Adults

3 (1 votes)

1 (1 votes)

Similar immune-system therapy has proven effective in children with this cancer as well as in adults with a similar type of leukemia, however, this is the first time this specific therapy has worked in adults.

The findings of the current study were based on five patients with acute lymphoblastic leukemia (ALL). T cells were extracted from the patient and modified to express a receptor for protein on other immune cells - called B cells - that are found in both cancerous and healthy tissues.

ALL is a cancer of the blood and bone marrow which progresses quickly - if left untreated, patients sometimes die within weeks. The first treatment is generally three phases of chemotherapy drugs.

For most patients, this puts the cancer in remission. However, it often comes back. The second treatment agenda is usually another round of chemotherapy followed by a bone marrow transplant.

The authors point out that when the cancer returns, it is often immune to many chemotherapy drugs. Therefore, Dr. Renier Brentjens, an oncologist at Memorial Sloan-Kettering Cancer Center in New York City, and his colleagues set out to test a different approach.

The five participating patients received infusions of their altered T cells after undergoing standard chemotherapy. All five patients saw a total remission - for one patient this occured within just eight days, according to the researchers.

Original post:
Cell Therapy Shows Promise For Advanced Leukemia In Adults

NEW YORK, March 18, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced that the Company's contract development and manufacturing ("CDMO") subsidiary, Progenitor Cell Therapy ("PCT"), has launched a new service offering, using a custom developed Internet/Web application to further its position as a technology leader for cell therapy. The new service, an automated software system called "PCTFORME.COM", resides in a highly secure, cloud based computing environment, available 24/7, and serves to enhance PCT's service offering to its growing client base. This service has been launched for a major client and is now available for all of PCT's existing and future stem cell clients.

PCTFORME allows PCT's clients to securely access patient details on-line and provides for real time product ordering, processing and retrieval via automated communications between PCT's clients and laboratory staff. The system is expected to significantly enhance communication by enabling easy tracking of current processing, increasing PCT's efficiencies and streamlining the process for the ordering of patient cells for infusion. PCTFORME is HIPAA compliant and built on a proven Microsoft software platform and supporting cloud based hardware infrastructure.

Robert A. Preti, PhD, President and Chief Scientific Officer of PCT, said, "The need to service the demand, in both volume and variety of procedures, continues to grow as PCT serves our client base. The efficiencies gained in order entry, cell product inventory management, and real time procedure result reporting is expected to improve patient care through enhanced communication, control and transparency. In this regard, PCTFORME represents a patient product management breakthrough in stem cell processing."

"As the field of cell therapy continues to emerge, we believe technology will enable us to reduce costs, better service our clients and build scalable operations to be ready for the future when cell therapy becomes standard of care in medical practice," said Dr. Robin L. Smith, Chairman and CEO of NeoStem. "Our management is focused on evaluating, developing and incorporating such technologies into our state-of-the-art contract development and manufacturing business to assist our clients, as well as our clinical development subsidiaries, with their cell therapy product development, and in preparation to launch them into the clinic."

About NeoStem, Inc.

NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. Our business model includes the development of novel proprietary cell therapy products as well as operating a contract development and manufacturing organization ("CDMO") providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation. http://www.neostem.com

About Progenitor Cell Therapy, LLC ("PCT")

PCT, a wholly owned subsidiary of NeoStem, Inc., is a leading CDMO in the cellular therapy industry. Since its inception in 1997, PCT has provided pre-clinical and clinical current Good Manufacturing Practice ("cGMP") development and manufacturing services to over 100 clients advancing regenerative medicine product candidates through rigorous quality standards all the way through to human testing. PCT has two cGMP, state-of-the art cell therapy research, development, and manufacturing facilities in New Jersey and California, serving the cell therapy community with integrated and regulatory compliant distribution capabilities. Its core competencies in the cellular therapy industry include manufacturing of cell therapy-based products, product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services. http://www.pctcelltherapy.com

Forward-Looking Statements for NeoStem, Inc.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, including with respect to the Company's or its partners' successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company's ability to successfully penetrate such markets and the market for its contract development and manufacturing business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. The Company's actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to matters described under the "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 11, 2013 and in the Company's other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

Go here to read the rest:
NeoStem's Subsidiary, Progenitor Cell Therapy , Launches Web-Based Service for Real-Time Cell Therapy Product Tracking

Stem cell therapy has been found useful in over 60 per cent of the patients due for liver transplant, as per a paper submitted by doctors at Sir Ganga Ram Hospital in Delhi recently. Not only is the treatment less cumbersome and risky, its cost is also comparatively very reasonable.

According to the papers principal author and chairman of the Department of Gastroenterology and Liver Diseases at the Hospital, Dr. Anil Arora, a large number of patients requiring liver transplantation cannot afford it for two reasons cost and donor availability.

A living donor is needed in such plantation cases with a matching blood group and he or she also has to be a family member or a first or second degree relative. They have to donate the liver. Since Rs.20 lakh is the average cost of liver transplantation, a majority of liver cirrhosis patients can not afford it. Many times they also do not have a donor, he said.

In view of the logistical problems faced by such patients, Dr. Arora said: We started looking at the feasibility of alternative methods like using reserve cells in the body called stem cells for such treatment as it costs even less than Rs.50,000. Some of these cells can be mobilised from the bone marrow as it has the capacity to regenerate the cells. So we stimulate the bone marrow by an injection.

This injection is given for five days and it mobilises the bone marrow and some of the cells. They then come into the blood circulation. In the study we tried to filter these cells from the blood marrow using a specialised filtering machine and the concentrate of these cells. About 5 ml to 10 ml of the blood containing these concentrated group of cells was then injected into the hepatic artery, which supplies blood to the liver, explained Dr. Arora. He said this process was carried out by a number of different mechanisms and it proved quite successful. We started about two years ago and finished last year. Then these patients were followed up for another one year and we were happy to see a significant proportion of the patients having substantial improvement in the liver functions as assessed by a score called Child score.

Dr. Arora said, All patients tolerated the treatment well without any side effects. Of the 10 patients, six to seven benefited. So we believe that more frequent administration of the stem cells in large number might have a more beneficial impact.

While the study by the Sir Ganga Ram Hospital team was published this year and was approved by the Department of Biotechnology and Ministry of Science and Technology, Government of India, Dr. Arora said there is also other published data now which calls for stimulating the bone marrow and letting the cells automatically go into the liver. By this, he said, you avoid filtering and putting the blood with the stem cells into the liver. This is also equally beneficial.

Dr. Arora said stem cell therapy might act as a bridge for liver transplant and can provide some time to the patients to arrange for treatment. But just like a damaged car tyre, he said, a damaged liver after minor repairs has to be replaced. However, if a person stops taking liquor or if the therapy goes on well, then a patient can lead a healthy life for many more years.

Read the original here:
Stem cell therapy is new hope for liver transplant patients

Cell Therapy for Allogeneic Stem Cell Transplant by Dr Richard Champlin
Dr Richard Champlin, Professor and Chair of the department of Stem Cell Transplant and Cellular Therapy gave an update on the role of Cell Therapy in improvi...

By: TheMedalGroup

View original post here:
Cell Therapy for Allogeneic Stem Cell Transplant by Dr Richard Champlin - Video

STEM CELL Therapy thru Laminine_Part-1(new link)
STEM CELL Therapy thru laminine_part1new link. Uploaded by cabmon0001 on Mar 14 2013. cabmon 0001.

By: cabmon0001

View original post here:
STEM CELL Therapy thru Laminine_Part-1(new link) - Video

STEM CELL Therapy thru Laminine_Part-2(new link)
STEM CELL Therapy thru laminine_part2new link. Uploaded by cabmon0001 on Mar 14 2013. cabmon 0001.

By: cabmon0001

See the rest here:
STEM CELL Therapy thru Laminine_Part-2(new link) - Video

LONDON (SHARECAST) - ReNeuron Group has won two grants worth 1.2m pounds to develop its stem cell therapy.

The grants were awarded by the UK Biomedical Catalyst, a programme of public funding jointly managed by the Technology Strategy Board and the Medical Research Council.

The first award of 0.4m will be used for ReNeurons ReN009 stem cell therapy candidate for critical limb ischaemia, a severe blockage in the arteries which markedly reduces blood-flow to the extremities including hands, feet and legs.

The second award of 0.8m relates to the company's ReN003 stem cell candidate for the treatment of retinitis pigmentosa, an eye disease in which there is damage to the retina.

Michael Hunt, the Chief Executive Officer of ReNeuron, said: "We are delighted to have been successful in winning the two grants we applied for in the current round of the Biomedical Catalyst funding competition.

"This highly competitive scheme involves a rigorous peer review of applicants' technologies and commercial development plans.

"In common with other awardees, we therefore regard the grants as representing a strong independent endorsement of ReNeuron's world-class stem cell development capabilities which we hope will eventually lead to the wide-scale treatment of disease conditions where there is currently a very large unmet medical need."

Shares rose 0.86% to 2.94p at 08:52 Monday.

RD

Read more from the original source:
ReNeuron Group wins grants for stem cell therapy development

With its growing popularity in the country, the so-called stem cell therapy, which was recently approved by the Department of Health (DOH), is now available in Davao City.

Dr. Luz Acosta, a Davao-born physician specializing in Ophthalmology, Oculoplastic Reconstructive Surgery, Cosmetic Surgery and recently Stem Cell Treatment, conducts the procedure after acquiring equipment from Australia and the USA. She is supported by a team that includes cardiologists, internists, and anesthesiologists who administer the laboratory tests and cardiopulmonary clearance to determine if an individual can safely undergo stem cell therapy. Having trained in this discipline abroad, she recently decided to offer this treatment after it was approved by the DoH.

As a founding member of the Philippine Society for Stem Cell Medicine that was only established last January 18, 2013 with DOH Sec. Dr. Enrique Ona as its honorary chair, Acosta is joined by doctors Jose Sabili, Melchor Santos, Christian Mancao, Leo Olarte, Bu Castro, Oscar Tinio, and Almond Derla as well as Mr. Rico Colayco as organizers of the society.

"This means that the Philippine Society for Stem Cell Medicine is the regulating body for the practice of stem cell treatment in the country," Acosta says. "Stem cell therapy is legal and safe for every medically cleared patient who wants to undergo such treatment to be rejuvenated and treated of his/her illnesses and diseases."

Acosta said that based on what was stipulated in the approved directions for stem cell therapy, the stem cell could just come from the person himself and not from the other sources like black sheep or aborted fetus, adding that sources of stem cells are fats, blood, bone marrow and umbilical cord.

"It could take five to six hours for one to undergo stem cell therapy. Harvesting is done in the first two hours, then another one to two hours for stem cell processing and activation, and the last one to two hours for treatment of stem cells back to the same patient," she said.

Popular personalities who have already publicly admitted that they had undergone stem cell therapy are former President Joseph Estrada, Senate President Juan Ponce Enrile and former Senator Ernesto Maceda, who said that they spent millions to pay for the treatment.

But Acosta said that it could be a lot cheaper here than abroad, as the cost of treatment will be in accordance to the guidelines of the Phil. Society for Stem Cell Medicine.

She said there have been very good clinical outcomes from stem cell treatments on autism, auto-immune diseases, cerebral palsy, diabetes, heart disease, liver cirrhosis, macular degeneration, multiple sclerosis, nerve damage, osteoarthritis, spinal cord injury and stroke.

"But we have to clarify here that we are not claiming stem cell therapy as a cure for cancer, though it can alleviate pain and improve patients' wellbeing while undergoing cancer therapy," she said.

Read more from the original source:
Stem Cell Therapy Now In Davao

Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy
Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy He is a known case of Myotonic MD with history of gradual onset of progressive lower extremities muscle weakness since age of 25 years. He also has history of delayed milestones. His weakness is progressive in nature. He falls while walking so walks with human support only. He has complaints of early fatigue and slurred speech due to tongue hypertrophy. He has atrophy of proximal muscles of all extremities. He has modified independence in almost all ADL. Neurologically, hypotonic, hyporeflexic. On examination: lower limb distal muscles are 0/5 on MMT while proximal muscles are having 2++/5 on MMT. Upper extremities left side proximal muscles are 1++/5 while right side proximal muscles are 3 #713;/5, distal muscles are 3++/5 in upper extremities. Functionally, modified independence in all ADL. On FIM he scores 99. After Stem Cell Treatment 1. His face looks more fresh. 2. His neck used to fall back previously but now he can control his neck well in each movement. 3. Back muscle strength has improved. 4. Bridging is better now. He can lift his back more up now which he couldn #39;t do at all. 5. His stamina has improved. 6. His shoulder strength has improved. Shoulder shrugging is better now. Active shoulder flexion, range of motion is more now. 7. Side lying to sitting he can do without any support which was not possible before. 8. Drooling of saliva from mouth in night is completely stopped. 9. His legs used ...

By: neurogenbsi

See the article here:
Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy - Video

Stem Cell Therapy for Autism Part 2
He is a known case of Autism with history of full term caesarean section delivery and cried immediately after birth with near normal motor milestones. But as he was put in school, there were regular complaints of him being hyperactive. He was then diagnosed to have Autism. He was shifted to special school then. Neurologically, he has near normal tone, reflexes and muscle power. On examination: he has hyperactivity. He has aggressive behaviour with episodes of violence and beating others. He has repetitive speech (echolalia), but it is need based. He has social isolation. He is bowel bladder trained. He is independent in most ADL. Functionally, he needs supervision in most ADL. On FIM he scores 106. After Stem Cell Therapy Psychology assessment: 1) Now his duration of expressing his anger has reduced (ie) previously he would get angry and it would continue for half an hour to 20 minutes. Now it has reduced to 10 minutes. 2) Now his level of understanding and tolerance level has increased (ie) before he would get upset even before his parents spoke whereas now he listens to them and follows commands. 3) Now he has started writing (ie) now he can copy from the book and he can do so for a duration of ½ hour to 1 hour which wasn #39;t possible at all before. 4) Previously he had obsessive features like washing his hands repetitively but now it has reduced. 5) Previously he would disturb others in the classroom by shouting or sitting next to them but now he doesn #39;t disturb others ...

By: neurogenbsi

View post:
Stem Cell Therapy for Autism Part 2 - Video